SCHEMBL5570709

SCHEMBL5570709

Cc1nc2c(O)c(CC=Cc3ccccc3)c(C(=O)N(C)C)cn2c1C

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ATP4A P20648 4/20 0.40
ATP4B P51164 4/20 0.40
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
RAB9A P51151 1/20 0.36
P2RX3 P56373 1/20 0.35
HDAC1 Q13547 3/20 0.32
HDAC2 Q92769 2/20 0.32
HDAC6 Q9UBN7 2/20 0.32
HDAC8 Q9BY41 1/20 0.32
PAM P19021 1/20 0.32
P2RX7 Q99572 1/20 0.32
BCHE P06276 1/20 0.32
ENPP3 O14638 1/20 0.32
ALPL P05186 1/20 0.32
XIAP P98170 1/20 0.32
PTGER4 P35408 1/20 0.32
PTGER3 P43115 1/20 0.32
PTGER2 P43116 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5570706 1.00 ATP4A (0.40) ATP4AATP4BALDH1A1KDM4ERAB9A
SCHEMBL4600666 0.90 ALDH1A1 (0.43) ATP4AATP4BALDH1A1KDM4ERAB9A
SCHEMBL4600661 0.90 ALDH1A1 (0.43) ATP4AATP4BALDH1A1KDM4ERAB9A
SCHEMBL5419975 0.84 RAB9A (0.37) ALDH1A1KDM4ERAB9AP2RX3HDAC1
SCHEMBL5419979 0.84 RAB9A (0.37) ALDH1A1KDM4ERAB9AP2RX3HDAC1
SCHEMBL4600103 0.83 ALDH1A1 (0.34) ATP4AATP4BALDH1A1KDM4ERAB9A
SCHEMBL5567379 0.81 ALDH1A1 (0.33) ATP4AATP4BALDH1A1KDM4ERAB9A
SCHEMBL5567375 0.81 ALDH1A1 (0.33) ATP4AATP4BALDH1A1KDM4ERAB9A
SCHEMBL4994479 0.79 KMT2A (0.36) ALDH1A1RAB9AP2RX7
SCHEMBL4600310 0.79 ALDH1A1 (0.46) ATP4AATP4BALDH1A1KDM4EP2RX3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070066674-A1 Tricyclic imidzopyridines for use as gastric secretion inhibitors ALTANA PHARMA AG (DE) 2007-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066674-A1 Tricyclic imidzopyridines for use as gastric secretion inhibitors GIPR, SLC10A2, GRPR ATP4A 96/4885ATP4B 259/4885ALDH1A1 1722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.